News

CMA Hails TGA Complementary Medicine Ticks

Approval by the Therapeutic Goods Administration (TGA) of ten new ingredients for use in listed medicines has been welcomed by Complementary Medicines Australia (CMA) which has advocated for removal of redundant regulatory burden.  The listing notice, published by the TGA on Fri, includes preparations that contain ribose, calcium pyruvate, magnesium pyruvate, octanoic acid, Terminalia arjuna, Berberis aristata, comethylcobalamin, choline dihydrogen citrate, Liepidium meyenii, Trachyspermum ammi and dimethylglycine hydrocholoride as a therapeutically active ingredient. 


CMA CEO Carl Gibson said: “We welcome this streamlining of ingredient approvals, resulting from recent work by the TGA towards greater collaboration with comparable international regulators and with industry.  “It is important to enhance competition and innovation in the industry by removing unnecessary regulation, whilst maintaining consumer confidence in the exceptional reputation of the Australian regulatory system.”  With many ingredients found safe overseas previously unavailable here, Australians “have been missing out on innovative new  products,” Gibson said.  “The complementary medicines industry is driven by consumers, meaning that the ability to innovate is vital to the sustainability of the complementary medicines industry, enabling companies to produce new products and meet consumer demands.”  “With an appropriate regulatory environment, the Australian complementary medicines industry will continue to grow and support high skilled manufacturing and local jobs,” he concluded.

Source: pharmacydaily.com.au, Monday 14 September 2015